drugset / Trial / NCT00504140

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

NCT00504140

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objectives: 1. To determine the efficacy of combining Interferon Alpha (IFN) with etoposide for the treatment of relapsed osteosarcoma. 2. To determine if IFN alters the plasma pharmacokinetics of etoposide. 3. To determine the toxicities of IFN and etoposide when administered together. 4. To determine IFN blood levels following combination therapy.

Timeline

Start
1996-11
Primary completion
2007-11
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject interferon alfa-2b Protein / enzyme biologic 5e+06 unknown Subcutaneous

Indications